Transforming ligands into transcriptional regulators: Building blocks for bifunctional molecules

Chemical Society Reviews

Volumn 40, Issue 8, 2011, Pages 4286-4294

  Højfeldt, Jonas W ^a   Dyke, Aaron R Van ^a   Mapp, Anna K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960516374     PISSN: 03060012     EISSN: 14604744     Source Type: Journal    
DOI: 10.1039/c1cs15050b     Document Type: Article

References (63)

1. G. Keller, Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 2005, 19, 1129-55
2. C. M. Perou, S. S. Jeffrey, M. van de Rijn, C. A. Rees, M. B. Eisen, D. T. Ross, A. Pergamenschikov, C. F. Williams, S. X. Zhu, J. C. Lee, D. Lashkari, D. Shalon, P. O. Brown, D. Botstein, Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 9212-7
3. P. P. Pandolfi, Transcription therapy for cancer. Oncogene 2001, 20, 3116-27
4. J. A. Rodriguez-Martinez, K. J. Peterson-Kaufman, A. Z. Ansari, Small-molecule regulators that mimic transcription factors. Biochim. Biophys. Acta 2010, 1799, 768-74
5. R. G. Roeder, Transcriptional regulation and the role of diverse coactivators in animal cells. FEBS Lett. 2005, 579, 909-15
6. G. Orphanides, D. Reinberg, A unified theory of gene expression. Cell 2002, 108, 439-51
7. K. Luger, A. W. Mader, R. K. Richmond, D. F. Sargent, T. J. Richmond, Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389, 251-60
8. J. J. Wyrick, F. C. Holstege, E. G. Jennings, H. C. Causton, D. Shore, M. Grunstein, E. S. Lander, R. A. Young, Chromosomal landscape of nucleosome-dependent gene expression and silencing in yeast. Nature 1999, 402, 418-21
9. C. Martinez-Campa, P. Politis, J. L. Moreau, N. Kent, J. Goodall, J. Mellor, C. R. Goding, Precise nucleosome positioning and the TATA box dictate requirements for the histone H4 tail and the bromodomain factor Bdf1. Mol. Cell 2004, 15, 69-81
10. C. Muchardt, M. Yaniv, ATP-dependent chromatin remodelling: SWI/SNF and Co. are on the job. J. Mol. Biol. 1999, 293, 187-98
11. T. Kouzarides, Chromatin modifications and their function. Cell 2007, 128, 693-705
12. R. E. Moellering, M. Cornejo, T. N. Davis, C. Del Bianco, J. C. Aster, S. C. Blacklow, A. L. Kung, D. G. Gilliland, G. L. Verdine, J. E. Bradner, Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462, 182-8
13. H. Gronemeyer, J. A. Gustafsson, V. Laudet, Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discovery 2004, 3, 950-64
14. H. L. Devlin, M. Mudryj, Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett. 2009, 274, 177-86
15. J. P. Overington, B. Al-Lazikani, A. L. Hopkins, How many drug targets are there?. Nat. Rev. Drug Discovery 2006, 5, 993-6
16. R. Kerkela, K. C. Woulfe, J. B. Durand, R. Vagnozzi, D. Kramer, T. F. Chu, C. Beahm, M. H. Chen, T. Force, Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2009, 2, 15-25
17. N. Ballas, C. Grunseich, D. D. Lu, J. C. Speh, G. Mandel, REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 2005, 121, 645-57
18. G. N. Fuller, X. Su, R. E. Price, Z. R. Cohen, F. F. Lang, R. Sawaya, S. Majumder, Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol. Cancer Ther. 2005, 4, 343-9
19. D. M. Spencer, T. J. Wandless, S. L. Schreiber, G. R. Crabtree, Controlling signal transduction with synthetic ligands. Science 1993, 262, 1019-24
20. A. Ullrich, J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-12
21. M. Ptashne and A. Gann, Genes and Signals, Cold Spring Harbor Laboratory Press, 2002
22. P. B. Dervan, Molecular recognition of DNA by small molecules. Bioorg. Med. Chem. 2001, 9, 2215-35
23. P. E. Nielsen, Peptide nucleic acid targeting of double-stranded DNA. Methods Enzymol. 2001, 340, 329-40
24. M. P. Cosma, T. Tanaka, K. Nasmyth, Ordered recruitment of transcription and chromatin remodeling factors to a cell cycle- and developmentally regulated promoter. Cell 1999, 97, 299-311
25. R. Metivier, G. Penot, M. R. Hubner, G. Reid, H. Brand, M. Kos, F. Gannon, Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115, 751-63
26. I. A. Hope, K. Struhl, Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast. Cell 1986, 46, 885-94
27. J. Ma, M. Ptashne, Deletion analysis of GAL4 defines two transcriptional activating segments. Cell 1987, 48, 847-53
28. J. Ma, M. Ptashne, A new class of yeast transcriptional activators. Cell 1987, 51, 113-9
29. E. Giniger, M. Ptashne, Transcription in yeast activated by a putative amphipathic alpha helix linked to a DNA binding unit. Nature 1987, 330, 670-2
30. A. R. Minter, B. B. Brennan, A. K. Mapp, A small molecule transcriptional activation domain. J. Am. Chem. Soc. 2004, 126, 10504-5
31. S. J. Buhrlage, B. B. Brennan, A. R. Minter, A. K. Mapp, Stereochemical promiscuity in artificial transcriptional activators. J. Am. Chem. Soc. 2005, 127, 12456-7
32. S. P. Rowe, R. J. Casey, B. B. Brennan, S. J. Buhrlage, A. K. Mapp, Transcriptional up-regulation in cells mediated by a small molecule. J. Am. Chem. Soc. 2007, 129, 10654-5
33. R. J. Casey, J. P. Desaulniers, J. W. Hojfeldt, A. K. Mapp, Expanding the repertoire of small molecule transcriptional activation domains. Bioorg. Med. Chem. 2009, 17, 1034-43
34. S. J. Buhrlage, C. A. Bates, S. P. Rowe, A. R. Minter, B. B. Brennan, C. Y. Majmudar, D. E. Wemmer, H. Al-Hashimi, A. K. Mapp, Amphipathic small molecules mimic the binding mode and function of endogenous transcription factors. ACS Chem. Biol. 2009, 4, 335-44
35. W. Xu, L. H. Kasper, S. Lerach, T. Jeevan, P. K. Brindle, Individual CREB-target genes dictate usage of distinct cAMP-responsive coactivation mechanisms. EMBO J. 2007, 26, 2890-903
36. D. C. Bedford, L. H. Kasper, T. Fukuyama, P. K. Brindle, Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics 2010, 5, 9-15
37. J. V. Frangioni, L. M. LaRiccia, L. C. Cantley, M. R. Montminy, Minimal activators that bind to the KIX domain of p300/CBP identified by phage display screening. Nat. Biotechnol. 2000, 18, 1080-5
38. S. P. Rowe, A. K. Mapp, Assessing the permissiveness of transcriptional activator binding sites. Biopolymers 2008, 89, 578-81
39. J. L. Best, C. A. Amezcua, B. Mayr, L. Flechner, C. M. Murawsky, B. Emerson, T. Zor, K. H. Gardner, M. Montminy, Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 17622-7
40. H. M. Volkman, S. E. Rutledge, A. Schepartz, Binding mode and transcriptional activation potential of high affinity ligands for the CBP KIX domain. J. Am. Chem. Soc. 2005, 127, 4649-58
41. X. Xiao, P. Yu, H. S. Lim, D. Sikder, T. Kodadek, A cell-permeable synthetic transcription factor mimic. Angew. Chem. Int. Ed. 2007, 46, 2865-8
42. S. Asada, Y. Choi, M. Uesugi, A gene-expression inhibitor that targets an alpha-helix-mediated protein interaction. J. Am. Chem. Soc. 2003, 125, 4992-3
43. Y. Kwon, H. D. Arndt, Q. Mao, Y. Choi, Y. Kawazoe, P. B. Dervan, M. Uesugi, Small molecule transcription factor mimic. J. Am. Chem. Soc. 2004, 126, 15940-1
44. D. Jung, H. Shimogawa, Y. Kwon, Q. Mao, S. Sato, S. Kamisuki, H. Kigoshi, M. Uesugi, Wrenchnolol derivative optimized for gene activation in cells. J. Am. Chem. Soc. 2009, 131, 4774-82
45. S. A. Johnston, J. M. Salmeron, S. S. Dincher, Interaction of positive and negative regulatory proteins in the galactose regulon of yeast. Cell 1987, 50, 143-6
46. Y. Han, T. Kodadek, Peptides selected to bind the Gal80 repressor are potent transcriptional activation domains in yeast. J. Biol. Chem. 2000, 275, 14979-84
47. S. Shangary, S. Wang, Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. 2009, 49, 223-41
48. J. X. Cheng, M. Gandolfi, M. Ptashne, Activation of the Gal1 gene of yeast by pairs of “non-classical” activators. Curr. Biol. 2004, 14, 1675-9
49. Z. Wu, G. Belanger, B. B. Brennan, J. K. Lum, A. R. Minter, S. P. Rowe, A. Plachetka, C. Y. Majmudar, A. K. Mapp, Targeting the transcriptional machinery with unique artificial transcriptional activators. J. Am. Chem. Soc. 2003, 125, 12390-1
50. C. Y. Majmudar, A. E. Labut, A. K. Mapp, Tra1 as a screening target for transcriptional activation domain discovery. Bioorg. Med. Chem. Lett. 2009, 19, 3733-5
51. A. L. Hopkins, C. R. Groom, The druggable genome. Nat. Rev. Drug Discovery 2002, 1, 727-30
52. R. A. Copeland, E. J. Olhava, M. P. Scott, Targeting epigenetic enzymes for drug discovery. Curr. Opin. Chem. Biol. 2010, 14, 505-10
53. B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, R. Pazdur, FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12, 1247-52
54. A. Ohtsuki, M. T. Kimura, M. Minoshima, T. Suzuki, M. Ikeda, T. Bando, H. Nagase, K. Shinohara, H. Sugiyama, Synthesis and properties of PI polyamide-SAHA conjugate. Tetrahedron Lett. 2009, 50, 7288-7292
55. T. Hayakawa, J. Nakayama, Physiological roles of class I HDAC complex and histone demethylase. J. Biomed. Biotechnol. 2011, 2011, 129383
56. K. T. Smith, S. A. Martin-Brown, L. Florens, M. P. Washburn, J. L. Workman, Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chem. Biol. 2010, 17, 65-74
57. S. Balasubramanian, E. Verner, J. J. Buggy, Isoform-specific histone deacetylase inhibitors: the next step?. Cancer Lett. 2009, 280, 211-21
58. W. Fischle, F. Dequiedt, M. J. Hendzel, M. G. Guenther, M. A. Lazar, W. Voelter, E. Verdin, Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 2002, 9, 45-57
59. A. Nebbioso, F. Manzo, M. Miceli, M. Conte, L. Manente, A. Baldi, A. De Luca, D. Rotili, S. Valente, A. Mai, A. Usiello, H. Gronemeyer, L. Altucci, Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 2009, 10, 776-82
60. R. Marmorstein, S. L. Berger, Structure and function of bromodomains in chromatin-regulating complexes. Gene 2001, 272, 1-9
61. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La Thangue, C. A. French, O. Wiest, A. L. Kung, S. Knapp, J. E. Bradner, Selective inhibition of BET bromodomains. Nature 2010, 468, 1067-1073
62. K. E. Hauschild, R. E. Metzler, H. D. Arndt, R. Moretti, M. Raffaelle, P. B. Dervan, A. Z. Ansari, Temperature-sensitive protein-DNA dimerizers. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 5008-13
63. R. Moretti, L. J. Donato, M. L. Brezinski, R. L. Stafford, H. Hoff, J. S. Thorson, P. B. Dervan, A. Z. Ansari, Targeted chemical wedges reveal the role of allosteric DNA modulation in protein-DNA assembly. ACS Chem. Biol. 2008, 3, 220-9